The Brazilian patent system is approaching a turning point. Five years after the Federal Supreme Court (STF) struck down the sole paragraph of Article 40 of the Brazilian Patent Statute during the trial...

China and Brazil's fifty-year diplomatic relationship has evolved into a strategic partnership where Chinese technology companies find a uniquely favorable patent enforcement environment. How does Brazil's unified federal patent system, high allowance rates for Chinese applicants, and effective standard-essential patent enforcement mechanisms position the country as a critical jurisdiction for Chinese innovators operating in telecommunications, automotive, and digital platforms?

Brazil's Life Sciences legal landscape is undergoing significant transformation through regulatory consolidation, pricing reforms, and evolving IP frameworks. Recent Supreme Court decisions on patent extensions and healthcare judicialization, combined with stricter CMED pricing controls, are reshaping market access strategies and creating both challenges and opportunities for pharmaceutical and biotech companies operating in this complex regulatory environment.

Brazil's grace period provision allows inventors to disclose their inventions up to 12 months before filing a patent application without jeopardizing patentability. However, applicants face significant evidential challenges when proving the disclosure originated from the inventor, particularly when documents are authored by employers or third parties, and must navigate examiner discretion in the absence of clear regulatory guidelines.

There are currently 30+ bills pending before the Brazilian Congress that were drafted for the purpose of amending the Brazilian Patent Statute.

Brazil's patent office has revised its examination guidelines for new use inventions in chemistry, particularly medical uses, following extensive stakeholder consultation. The updated rules now permit post-filing data under certain conditions while maintaining restrictions on dosage regimen and patient group claims, creating a mixed landscape for pharmaceutical patent protection in Latin America's largest market.

Brazil's bio-input industry has experienced remarkable growth, generating BRL 4.5 billion in revenue in 2024—a sixfold increase since 2019. With over 1,000 registered bio-inputs...

OpenAI's groundbreaking decision to launch its first AI guidebook for teenagers in Brazil signals a pivotal moment in the intersection of technology, education, and digital rights. What factors led this global AI leader to select Brazil as the testing ground for youth AI literacy, and how does the country's sophisticated legal framework position it as a model for responsible AI governance?

The patent system promises inventors exclusive rights in exchange for public disclosure, but enforcement has become prohibitively expensive, creating a minimum damages threshold that effectively rations access to justice. Litigation finance and contingency arrangements have emerged not as exploitation but as necessary responses to a system where defending patent rights can cost $12-20 million, making infringement economically rational even when patents are strong.

Brazil's health regulatory agency Anvisa has approved the opening of an administrative process to regulate the sale and delivery of medicines through digital marketplaces, aiming to update sanitary rules to reflect the reality of online pharmaceutical retail that has evolved far beyond the outdated 2009 regulations. The decision comes after Law 15.357/2026 authorized pharmacies to contract digital platforms for logistics and delivery services, yet significant legal uncertainties remain about compliance requ

The patent system promises inventors exclusive rights in exchange for public disclosure, but enforcement has become prohibitively expensive, creating a minimum damages threshold that effectively rations access to justice. This examination explores how litigation costs ranging from $12-20 million, combined with delay tactics and limited injunctive relief, have transformed infringement into an economically rational strategy even when patents are strong.

Digital signatures have revolutionized contract formalization in Brazil, offering efficiency and legal security through electronic authentication. How do Brazilian laws and court precedents establish the validity of digital signatures, and what practical implications do platforms like DocuSign have for businesses navigating this evolving legal landscape?

Once again, the Ministry of Health (MoH) changes the market share of PDPs involving monoclonal antibodies and etanercept.

Eduardo Hallak, founding partner of Licks Attorneys in Brazil, delivered a comprehensive analysis of Brazil's medical device market structure, regulatory framework, and patent protection system at the 6th IP Forefront Medical Device Forum. The presentation explored strategic pathways for Chinese medical device companies to enter the Brazilian market, including Product Development Partnerships, ANVISA regulatory compliance, and patent portfolio optimization within Latin America's largest healthcare market.

Brazil's new Statute #15,471 elevates the National Health Strategy for the Health Economic-Industrial Complex to statutory level, transforming a government program into a State program while introducing significant changes to Product Development Partnerships, procurement processes, and technology transfer requirements.

Artificial intelligence is revolutionizing the legal sector in Brazil, prompting unprecedented regulatory responses from key institutions. The Brazilian Bar Association and National Council of Justice have issued comprehensive frameworks addressing ethical AI use, data protection, algorithmic transparency, and human oversight in legal practice and judicial proceedings.

The Foreign Corrupt Practices Act has undergone significant transformation since its 1977 enactment, from a pioneering anti-corruption statute to a strategically refocused enforcement tool. Following President Trump's controversial 180-day suspension in 2025, new DOJ guidance has fundamentally altered how the United States prioritizes and prosecutes international bribery cases. What does this shift mean for global anti-corruption efforts and American companies operating abroad?

A lei 15.471/26 instituiu a Estratégia Nacional de Saúde do Complexo Econômico-Industrial da Saúde (ENSCEIS), conferindo status legal a políticas anteriormente baseadas apenas em atos infralegais. Embora represente avanços ao consolidar programas como as Parcerias para o Desenvolvimento Produtivo (PDPs), a nova legislação apresenta falhas de clareza, insegurança jurídica em disposições importantes e riscos de criar reservas de mercado que podem pos

On Friday, June 19, 2026, the Brazilian Patent and Trademark Office (BRPTO) published a report prepared by the Working Group on the Revision of Law #9,279/96 (the Brazilian Patent Statute...

O setor de defensivos agrícolas enfrenta atrasos crônicos na avaliação de registros pelo IBAMA, com processos pendentes por mais de 5 anos em média. Diante da morosidade sistemática e possíveis falhas de governança, o TCU autorizou auditoria operacional para verificar o cumprimento da Lei 14.785/23, examinar a aderência do órgão ao novo marco regulatório e avaliar questões de transparência e gestão administrativa.